Sign Up Today and Learn More About QED Therapeutics Stock
Invest in or calculate the value of your shares in QED Therapeutics or other pre-IPO companies through EquityZen's platform.
QED Therapeutics Stock (QETH)
Precision medicine for FGFR-driven disorders
About QED Therapeutics Stock
Headquarters
Palo Alto, CA, US
Total Funding
65.0M
Industries
Science and Engineering, Health Care, Biotechnology
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Their lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
QED Therapeutics Press Mentions
Stay in the know about the latest news on QED Therapeutics
BridgeBio out-licenses infigratinib in Japan
thepharmaletter • Apr 07, 2024
BridgeBio sells partial rights to dwarfism drug for $100M
finance • Mar 02, 2024
Kyowa pays $100M up front for Bridgebio's infigratinib in Japan
bioworld • Mar 02, 2024
For $100M, BridgeBio partners with Kyowa Kirin on infigratinib
fiercepharma • Mar 02, 2024
BridgeBio Pharma and QED Therapeutics License Skeletal Dysplasias Treatments to Kyowa Kirin for an Upfront ...
goodwinlaw • Mar 02, 2024
Investors in QED Therapeutics
Discover investors in QED Therapeutics stock and explore their portfolio companies
QED Therapeutics Management
Leadership team at QED Therapeutics
President
Neil Kumar
Chief Revenue Officer
Curtis Scribner
Join now and verify your accreditation status to gain access to:
- QED Therapeutics current valuation
- QED Therapeutics stock price
- Available deals in QED Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in QED Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like QED Therapeutics through EquityZen funds. These investments are made available by existing QED Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell QED Therapeutics stock?
Shareholders can sell their QED Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
